



A WORKSHOP

NATIONAL
ACADEMIES

Sciences
Engineering
Medicine

Adult Attention-Deficit/ Hyperactivity Disorder

**Diagnosis, Treatment, and
Implications for Drug Development**

Day 1 December 12 • 9:00AM – 5:00PM EST

Day 2 December 13 • 8:30AM – 2:00PM EST

NATIONAL
ACADEMIES

Sciences
Engineering
Medicine

Adult Attention-Deficit/Hyperactivity Disorder: Diagnosis, Treatment, & Implications for Drug Development - A Workshop

Craig Surman, *Workshop Co-Chair*

Massachusetts General Hospital &
Harvard Medical School



Workshop Funding and Disclaimers

This workshop is supported by:

- The National Academies Forum on Drug Discovery, Development and Translation
- The National Academies Forum on Neuroscience and Nervous System Disorders
- A grant (PAR-23-072) from the Center for Drug Evaluation and Research at the FDA.

Statements, recommendations, and opinions expressed here today are those of individual presenters and participants and are not necessarily endorsed or verified by the National Academies.

Discussions should not be construed as reflecting any group consensus.

Sponsors: Forum on Drug Discovery, Development, and Translation

Government

Center for Drug Evaluation and Research, FDA
National Cancer Institute, NIH
National Center for Advancing Translational Sciences, NIH
National Institute of Allergy and Infectious Diseases, NIH
National Institute of Mental Health, NIH
National Institute of Neurological Disorders and Stroke, NIH
Office of the Director, NIH

Nonprofit Organizations

Association of American Medical Colleges
Critical Path Institute
FasterCures, Milken Institute
Foundation for the National Institutes of Health
Friends of Cancer Research
New England Journal of Medicine

Private Foundation

Burroughs Wellcome Fund

Industry

Amgen Inc.
AstraZeneca
Biogen
Eli Lilly and Company
Johnson & Johnson
Medable
Merck & Co., Inc.
Sanofi

Forum on Drug Discovery, Development, and Translation Membership

- **Gregory E. Simon, Co-Chair**
Kaiser Permanente Washington Health Research Institute and University of Washington
- **Ann Taylor, Co-Chair, Retired**
- Barbara E. Bierer, Harvard Medical School
- Linda S. Brady, National Institute of Mental Health, NIH
- John Buse, University of North Carolina, Chapel Hill School of Medicine
- Luther T. Clark, Merck & Co., Inc.
- Barry S. Collier, The Rockefeller University
- Tammy R.L. Collins, Burroughs Wellcome Fund
- Thomas Curran, Children's Mercy, Kansas City
- Richard T. Davey
National Institute of Allergy and Infectious Diseases, NIH
- Katherine Dawson, Biogen
- James H. Doroshow, National Cancer Institute, NIH
- Jeffrey M. Drazen, *New England Journal of Medicine*
- Steven K. Galson, *Retired*
- Carlos Garner, Eli Lilly and Company
- Sally L. Hodder, West Virginia University
- Tesheia Johnson, Yale School of Medicine
- Lyric A. Jorgenson, Office of Science Policy, NIH
- Esther Krofah, FasterCures, Milken Institute
- Lisa M. LaVange, University of North Carolina Gillings School of Global Public Health
- Aran Maree, Johnson & Johnson
- Cristian Massacesi, AstraZeneca
- Ross McKinney, Jr., Association of American Medical Colleges
- Joseph P. Menetski, Foundation for the National Institutes of Health
- Anaeze C. Offodile II, Memorial Sloan Kettering Cancer Center
- Sally Okun, Clinical Trials Transformation Initiative
- Arti K. Rai, Duke University School of Law
- Klaus Romero, Critical Path Institute
- Joni Rutter, National Center for Advancing Translational Sciences, NIH
- Susan Schaeffer, The Patients' Academy for Research Advocacy
- Anantha Shekhar, University of Pittsburgh School of Medicine
- Ellen V. Sigal, Friends of Cancer Research
- Amir Tamiz, National Institute of Neurological Disorders and Stroke, NIH
- Pamela Tenaerts, Medable
- Jonathan Watanabe, University of California Irvine
- Alastair J. Wood, Vanderbilt University
- Cris Woolston, Sanofi
- Joseph C. Wu, Stanford University School of Medicine

Sponsors: Forum on Neuroscience and Nervous System Disorders

Academia

The George & Anne Ryan Institute for Neuroscience at the
University of Rhode Island
University of Rhode Island

Government

California Institute for Regenerative Medicine
Department of Veterans Affairs
Food and Drug Administration
National Center for Complementary and Integrative Health
National Eye Institute
National Institute of Environmental Health Sciences
National Institute of Mental Health
National Institute of Neurological Disorders and Stroke
National Institute on Aging
National Institute on Alcohol Abuse and Alcoholism
National Institute on Drug Abuse
National Institutes of Health BRAIN Initiative
National Science Foundation

Professional Society

American Neurological Association

Industry

Acadia Pharmaceuticals
Boehringer Ingelheim
Cerevel Therapeutics
Eisai
Harmony Biosciences
Janssen Research & Development, LLC
Karuna Therapeutics
Lundbeck Research USA, Inc
Takeda

Non-Profit Organizations

Alzheimer's Association
American Brain Coalition
BrightFocus Foundation
Cohen Veterans Bioscience
Foundation for the National Institutes of Health
Michael J. Fox Foundation for Parkinson's Research
National Multiple Sclerosis Society
One Mind
Paul G. Allen Frontiers Group

Private Foundation

Gatsby Charitable Foundation
Wellcome Trust

Forum on Neuroscience and Nervous System Disorders Membership

- **Frances Jensen, MD, Co-Chair**
University of Pennsylvania
- **John Krystal, MD, Co-chair**
Yale University
- Rita Balice-Gordon, PhD
Muna Therapeutics
- Deanna Barch, PhD
Washington University in St. Louis
- Diane Bovenkamp, PhD
BrightFocus Foundation
- Katja Brose, PhD
Chan Zuckerberg Initiative
- Teresa Buracchio, MD
Food and Drug Administration
- Sarah Caddick, PhD
Gatsby Charitable Foundation
- Rosa Canet-Avilés, PhD
California Institute for Regenerative Medicine (CIRM)
- Maria Carrillo, PhD
Alzheimer's Association
- Michael Chiang, MD
National Eye Institute
- Tim Coetzee, PhD
National Multiple Sclerosis Society
- Beverly Davidson, PhD
Children's Hospital of Philadelphia
- Nita Farahany, JD, PhD
Duke University
- Eva Feldman, MD, PhD
University of Michigan
- Brian Fiske, PhD
The Michael J. Fox Foundation for Parkinson's Research
- Joshua Gordon, MD, PhD
National Institute of Mental Health
- Morten Grunnet, PhD
Lundbeck
- Magali Haas, MD, PhD, MSE
Cohen Veterans Bioscience
- Richard Hodes, MD
National Institute on Aging
- Stuart Hoffman, PhD
Department of Veterans Affairs
- Yasmin Hurd, PhD
Icahn School of Medicine at Mount Sinai
- Steven Hyman, MD
Broad Institute of MIT and Harvard
- Michael Irizarry, MD
Eisai
- George Koob, PhD
National Institute on Alcohol Abuse and Alcoholism
- Walter Koroshetz, MD
National Institute of Neurological Disorders and Stroke
- Robert Malenka, MD, PhD
Stanford University
- Hussein Manji, MD, FRCP
Oxford University; Duke University; UK Government Mental Health Mission
- Hugh Marston, PhD
Boehringer Ingelheim
- Bill Martin, PhD
Janssen Research & Development
- John Ngai, PhD
National Institute of Health's Brain Research through Advancing Innovative Neurotechnologies (BRAIN®) Initiative
- Gentry Patrick, PhD
University of California San Diego
- Steve Paul, MD
Karuna Therapeutics
- Kathryn Richmond, MBA, PhD
Allen Institute
- M. Elizabeth Ross, MD, PhD, FANA
American Neurological Association
- Marsie Ross, PharmD
Harmony Biosciences
- Katie Sale, BA
American Brain Coalition
- Raymond Sanchez, MD
Cerevel Therapeutics
- Terrence Sejnowski, PhD
Salk Institute for Biological Studies
- Sarah Sheikh, MSc, BMBCh
Takeda
- Sarah Shnider, PhD, MSc
One Mind
- David Shurtleff, PhD
National Center for Complementary and Integrative Health
- John Spiro, PhD
Simons Foundation
- Alessio Travaglia, PhD
Foundation for the National Institutes of Health
- Nora Volkow, MD
National Institute on Drug Abuse
- Doug Williamson, MBChB, MRCPsych
Acadia Pharmaceuticals, Inc
- Richard Woychik, PhD
National Institute of Environmental Health Sciences
- Stevin Zorn, PhD
MindImmune Therapeutics

Workshop Planning Committee

Carlos Blanco (co-chair)

National Institute on Drug Abuse (NIDA)

Craig B.H. Surman (co-chair)

Massachusetts General Hospital; Harvard University

Amy F.T. Arnsten

Yale University

Andrea M. Chronis-Tuscano

University of Maryland

Taleed El-Sabawi

Florida International University

Tamara Rosier

ADHD Center of West Michigan, ADHD Coaches
Organization

Evelyn Polk Green

Attention Deficit Disorder Association (ADDA),
Children and Adults with Attention-
Deficit/Hyperactivity Disorder (CHADD)

Steve S. Lee

University of California, Los Angeles (UCLA)

James (Jimmy) Leonard

Maryland Poison Center; University of Maryland

Matthew Rudorfer

National Institute of Mental Health (NIMH)

Almut G. Winterstein

University of Florida

Stevin H. Zorn

MindImmune Therapeutics Inc.

Adult ADHD: Diagnosis, Treatment, & Implications for Drug Development – A Workshop (December 12-13, 2023)

Statement of Task

The workshop will feature invited presentations and discussions addressing:

- Discuss the criteria for diagnosis and treatment of adults with ADHD, taking into consideration health disparities and perspectives of people with lived experience.
- Consider what is known and unknown about the risks and benefits of ADHD medication use in adult populations.
- Share perspectives on the causes, perceptions, consequences, and health equity implications of non-medical use of prescription stimulants, including misuse potential, overdose, and toxicity.
- Explore challenges and opportunities for the development of new and improved therapeutics for the treatment of ADHD.
- Consider potential strategies for assessing the risks and benefits of ADHD medication treatment in adult populations, including the intersection with opioid use, that support the public health goal of safely and effectively treating adults with ADHD.

Agenda: Day 1 (December 12)

Opening Remarks

Understanding ADHD In Adults &
Regulatory Overview

Session 1

Diagnosis Of Adults With ADHD

Session 2

Medication Options For Adults With
ADHD: Risks And Benefits

Session 3

Implications For Drug Development

Session 4

Day 1 Synthesis And Discussion

Audience Q&A

End of Day 1

Reception in Keck Atrium

Agenda: Day 2 (December 13)

Opening Remarks
Fireside Chat

Session 5
Enabling Access to Resources and
Shared Decision Making For Adults
With ADHD And Their Providers

Session 6
Public Health Considerations and Harm
Reduction Strategies For ADHD
Medication Use

Session 7
Day 1 Synthesis and Discussion

Audience Q&A


Adjourn Workshop

Bullying and Harassment Policy

The National Academies provides a neutral venue where conflicting viewpoints can discuss issues of importance with respect. All forms of discrimination, harassment, and bullying are prohibited in any National Academies activity. This includes unwelcome and/or aggressive behavior involving the use of influence, threat, intimidation, or coercion to dominate others in the professional environment. We look to you to be a partner in this commitment by helping us to maintain a cordial environment.


After the Workshop

- Forum on Drug Discovery, Development, and Translation



nationalacademies.org/DrugForum

- Event Page - Adult ADHD: Diagnosis, Treatment, and Implications for Drug Development



nationalacademies.org/adhd